Targeting Cardiac Fibrosis With a Vaccine Against Fibroblast Activation Protein

Circulation Research, Journal Year: 2025, Volume and Issue: 136(1), P. 41 - 43

Published: Jan. 2, 2025

Language: Английский

---

Chimeric Antigen Receptor Cell Therapy: Empowering Treatment Strategies for Solid Tumors

Current Issues in Molecular Biology, Journal Year: 2025, Volume and Issue: 47(2), P. 90 - 90

Published: Jan. 31, 2025

Chimeric antigen receptor-T (CAR-T) cell therapy has demonstrated impressive efficacy in the treatment of blood cancers; however, its effectiveness against solid tumors been significantly limited. The differences arise from a range difficulties linked to tumors, including an unfriendly tumor microenvironment, variability within and barriers CAR-T infiltration longevity at location. Research shows that reasons for decreased cells treating are not well understood, highlighting ongoing need strategies address these challenges. Current frequently incorporate combinatorial therapies designed boost functionality enhance their capacity effectively target tumors. However, remain testing phase necessitate additional validation assess potential benefits. CAR-NK (natural killer), CAR-iNKT (invariant natural killer T), CAR-M (macrophage) emerging as promising Recent studies highlight construction optimization cells, emphasizing overcome unique challenges posed by such hypoxia metabolic barriers. This review focuses on CAR

Language: Английский

---

Enhancing CAR T-Cell Function with Domains of Innate Immunity Sensors

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(3), P. 1339 - 1339

Published: Feb. 5, 2025

The innate immune system plays an important role in protecting the organism via recognizing danger signals and pathogens through pattern recognition receptors. By sensing signal conveying signaling towards elimination of threat, several families these receptors, expressed on different myeloid lymphoid cells, serve as first defense line immunity. Toll-like C-type lectin many other receptors therefore illustrate importance protective system. This was additionally confirmed by CAR T-cell-based cancer immunotherapy, where patient’s own is being used for successful tumor elimination. T-cells have proven themselves to be a potent therapeutic option, yet some cases their efficiency could enhanced. Innate sensors that include strong activation domains, instance, part MyD88 (Myeloid Differentiation Primary Response gene), NKG2D (Natural killer group 2-member D), building module increase functionality potency T-cells.

Language: Английский

---

Deciphering the role of CNIH4 in pan-cancer landscapes and its significance in breast cancer progression

Frontiers in Genetics, Journal Year: 2025, Volume and Issue: 16

Published: Feb. 20, 2025

The escalating global cancer burden necessitates the development of biomarkers with enhanced specificity and sensitivity for early diagnosis therapeutic efficacy monitoring. CNIH4 gene, an emerging biomarker, is increasingly recognized its role in malignant progression across various cancers. We conducted a comprehensive multi-omics analysis CNIH4, including pan-cancer expression profiles, epigenetic alterations, immune microenvironment characteristics, response patterns. Our focus was on clinical features, molecular underpinnings, drug breast (BRCA) associated CNIH4. In vitro studies were also performed to assess effects knockdown cell proliferation cycle MDA-MB-231 line. upregulation observed multiple cancers, significantly correlating genomic instability. High levels linked poor prognosis cancers key cancer-related pathways, particularly those regulation DNA repair. Correlation analyses suggest tumor microenvironment, as evidenced by association subtypes, immune-related genes, infiltration. Single-cell spatial transcriptome confirmed that BRCA predicts malignancy. Drug revealed significant correlation between responsiveness kinase inhibitors chemotherapeutic agents. experiments demonstrated impacts cells. study highlights promising biomarker implications critical BRCA.

Language: Английский

---

Mesothelin-targeted CAR-T cells secreting NKG2D-BiTEs exhibit potent efficacy against triple-negative breast cancer

Experimental Hematology and Oncology, Journal Year: 2025, Volume and Issue: 14(1)

Published: March 3, 2025

Language: Английский

---

NKG2D/CD28 chimeric receptor boosts cytotoxicity and durability of CAR-T cells for solid and hematological tumors

Experimental Hematology and Oncology, Journal Year: 2025, Volume and Issue: 14(1)

Published: April 3, 2025

Abstract Background CAR-T cell therapy faces challenges in solid tumor treatment and hematologic malignancy relapse, among which the limited persistence of cells target antigen downregulation are prominent factors. Therefore, we engineered an NKG2D/CD28 chimeric co-stimulatory receptor (CCR), leveraging its broad ligand expression on tumors to enhance antitumor activity MSLN CAR CD19 cells. Methods We generated co-expressing CCR assessed their efficacy vitro vivo. activation, differentiation, exhaustion were analyzed over time following stimulation. Furthermore, a chronic stimulation model was established using with low density simulate sustained antigenic pressure encountered vivo conditions. Results Our study shows that NKG2D/CD28&CAR-T exhibit enhanced cytotoxicity against cells, especially those density, both Compared conventional second-generation or these dual-targeted demonstrate superior sensitivity recognizing lysing low-density antigen-expressing lung cancer leukemia they capable eradicating complementary co-stimulation provided by 4-1BB CD28 intracellular domains promotes cytokine secretion, reduces exhaustion, enhances significantly improving efficacy. Conclusion The combination offers potent strategy durability This approach is promising for therapeutic outcomes hematological preventing recurrence density.

Language: Английский

---

Drug delivery for age-related bone diseases: From therapeutic targets to common and emerging therapeutic strategies

Saudi Pharmaceutical Journal, Journal Year: 2024, Volume and Issue: 32(12), P. 102209 - 102209

Published: Nov. 24, 2024

Language: Английский

---